Abstract Number: 0102 • ACR Convergence 2026
Shared synovial and immune-cell serum signatures are associated with methotrexate-modulated clinical improvement in Early Rheumatoid Arthritis
Background/Purpose: The cellular origin of the circulating inflammatory proteome in early rheumatoid arthritis (RA) and its modulation by methotrexate (MTX) remain unclear. We aimed to…Abstract Number: 0444 • ACR Convergence 2026
Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate Versus Biologic DMARDs: A Real-World Analysis
Background/Purpose: Rheumatoid arthritis (RA) is associated with a higher risk of venous thromboembolism (VTE) compared with the general population. The comparative risk of VTE among…Abstract Number: 0671 • ACR Convergence 2026
A Ten-Year Descriptive Study of IgG4-Related Disease at a Tertiary Care Center in New York City
Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is a systemic fibroinflammatory condition that mimics malignancy, infection, and other autoimmune disorders. The most common organs involved are the…Abstract Number: 0989 • ACR Convergence 2026
Mycophenolate Mofetil Shows Differential Modulation of Skin Gene Expression Across Autoantibody Subgroups of Diffuse Cutaneous Systemic Sclerosis
Background/Purpose: Mycophenolate Mofetil (MMF) is standard of care therapy in systemic sclerosis (SSc) and recent clinical trial datasets show that MMF improves skin and lung…Abstract Number: 1330 • ACR Convergence 2026
Survival Of Biological Therapy According To Sex And HLA-B27 Positivity In Patients With Spondyloarthritis
Background/Purpose: Biological therapy survival is a robust surrogate marker of effectiveness in real-world clinical practice. Clinical and demographic factors, including sex and HLA-B27 status, may…Abstract Number: 1600 • ACR Convergence 2026
Prospective Validation of DMOMS, A Novel Dermatomyositis-Specific Endpoint, in the Phase 3 VALOR Trial
Background/Purpose: Skin disease is central to dermatomyositis (DM) but is not directly reflected in traditional myositis registrational endpoints including the Total Improvement Score (TIS). The…Abstract Number: 2213 • ACR Convergence 2026
Long-term Multidomain Clinical Response to Deucravacitinib in SLE: Four-Year Integrated Analyses From a Phase 2 Randomized Study and Its Long-Term Extension
Background/Purpose: Deucravacitinib (DEUC), an oral selective tyrosine kinase 2 (TYK2) inhibitor, demonstrated superior efficacy vs placebo (PBO) in patients with SLE in the phase 2…Abstract Number: 2591 • ACR Convergence 2026
JAK Inhibitors in Dermatomyositis: A Real-World Propensity-Matched Analysis of Mortality and Cardiovascular Outcomes
Background/Purpose: Dermatomyositis (DM) is an autoimmune inflammatory myopathy with significant mortality; yet with limited FDA-approved treatments available for disease management. Janus Kinase inhibitors (JAK) are…Abstract Number: 2933 • ACR Convergence 2026
Large-Scale Plasma Proteomics Identifies Orosomucoid 1 as a Circulating Predictor of Difficult-to-Treat Rheumatoid Arthritis
Background/Purpose: Despite biologic (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs), approximately 10.9% of rheumatoid arthritis (RA)1 patients meet the EULAR definition of difficult-to-treat…Abstract Number: 0130 • ACR Convergence 2026
Genetic Predisposition to Leukopenia in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune condition often managed with disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, and leflunomide. A challenge in…Abstract Number: 0445 • ACR Convergence 2026
Comparison of Cancer Risk in Patients with Rheumatoid Arthritis Treated with Methotrexate Versus Biologic-DMARDs: A Real-World Analysis
Background/Purpose: Malignancy risk with biologic DMARDs (bDMARDs) in rheumatoid arthritis (RA) remains controversial, with mixed evidence from clinical trials and observational studies. Real-world comparative data…Abstract Number: 0672 • ACR Convergence 2026
Active Cardiac Sarcoidosis Resolution Without Steroids: Retrospective Single-Center Analysis
Background/Purpose: The first-line management of active cardiac sarcoidosis (CS) according to the American Heart Association is prednisone 30-40 mg/day (or its equivalent). Methotrexate (MTX) is…Abstract Number: 1041 • ACR Convergence 2026
CP-RhA01 Reduces Stromal Pseudo-Resistance Across Autoimmune Disease Models by Metabolic Decoupling of a Pathological Stromal-Immune Loop
Background/Purpose: In rheumatoid arthritis (RA) and related autoimmune diseases, disease persistence may be sustained by a pathological stromal-immune feed-forward loop comprising activated fibroblast-like synoviocytes (FLS),…Abstract Number: 1342 • ACR Convergence 2026
Frequency and Predictors of Drug Free Remission in Psoriatic Arthritis: Insights from a Longitudinal Cohort
Background/Purpose: The therapeutic landscape of psoriatic arthritis (PsA) has evolved substantially over the past two decades with the introduction of targeted advanced therapies. Remission is the primary…Abstract Number: 1637 • ACR Convergence 2026
Seeing an Alternative: The Role of Leflunomide in Autoimmune Eye Disease
Background/Purpose: Treatment options for autoimmune eye disease (AED) are limited. In patients with contraindications to MTX and restricted access to biologics, non-biologic DMARD options are…
ACR Meeting Abstracts